Delving into the Latest Updates on Novacyte Therapeutics Company., Ltd with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	2

Top 5 Target	Count

HER2 x Tubulin	1
Tubulin x tissue factor	1

(1) Primary objective: To evaluate the safety and tolerability of NC18 in patients with HER2-positive or HER2-expressing advanced solid tumors, and to determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of NC18. (2) Secondary objective: To evaluate the pharmacokinetic (PK) characteristics, immunogenicity and efficacy of NC18.

Start Date25 Jun 2024

Sponsor / Collaborator

Nuo Ling Sheng Wu Yi Yao Ke Ji （ Hang Zhou ） You Xian Gong Si

100 Clinical Results associated with Novacyte Therapeutics Company., Ltd

Login to view more data

0 Patents (Medical) associated with Novacyte Therapeutics Company., Ltd

Login to view more data

100 Deals associated with Novacyte Therapeutics Company., Ltd

Login to view more data

100 Translational Medicine associated with Novacyte Therapeutics Company., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 1 Clinical

Login to view more data